Milan, Italy: Pierre Fabre Pharmaceuticals and BMG Pharma S.r.l announce the signature of a Distribution and Supply Agreement for AFTACURE Gel and AFTACURE Spray in different territories

May 15th 2017: * Pierre Fabre Oral Care, a brand of Pierre Fabre Pharmaceuticals, is one of the leaders in Europe in oral and dental hygiene products with its ranges of products presented to dentists across Europe 
* Thanks to this agreement in line with its open innovation strategy, Pierre Fabre Oral Care expands  and completes its portfolio with two original BMG PHARMA products

Milan (Italy), Castres (France), May 15th 2017: Pierre Fabre Pharmaceuticals, the second-largest French private pharmaceutical laboratory, and BMG Pharma S.r.l., an Italian innovative specialty pharmaceutical company, announce the signature of an International Distribution and Supply Agreement for two BMG original oral and dental hygiene products: Aftacure Gel and Aftacure Spray.
Under the terms of the agreement, the Pierre Fabre Oral Care brand (PFOC) of Pierre Fabre Pharmaceuticals will get the rights to distribute and commercialize Aftacure Gel and Aftacure Spray under its trademark “Elgydium Clinic” in different territories worldwide. Pierre Fabre Oral Care already benefits from a strong recognition from dentists, hygienists and pharmacists, as well as from expert learned societies worldwide. Aftacure Gel and Aftacure Spray will expand their range of products in these countries and strengthen their position.

“We have a strong position in Europe and one of our commitment is to provide the markets with the best and most comprehensive ranges of Oral and Dental Hygiene products. We therefore rely on our dedicated R&D team to launch innovative products, but we also develop partnerships with specialized companies to pool our skills. This agreement with BMG Pharma illustrates this open innovation strategy and our will to complete our offer.” said Pascal Lefrançois, Head of Pierre Fabre Consumer Health Care

“We are very proud to cooperate with Pierre Fabre Oral Care, a brand of Pierre Fabre Consumer Health Care, one of the leading pharmaceutical company in Europe which recognized the value and novelty of our products” – said Marco Mastrodonato, CEO of BMG Pharma S.r.l. – “We are very pleased to offer our products Aftacure Gel and Aftacure Spray, which under Pierre Fabre’s knowledge and experience will reach a large number of patients allowing them to receive fast pain relief for mouth lesions. This partnership is a major milestone for BMG as it allows our company to enlarge its market opportunity in the pharmaceutical world.”

About Aftacure Gel and Aftacure Spray

Aftacure Gel and Aftacure Spray have been registered in Europe as medical devices for several years and their key ingredients – PVP, taurine, zinc gluconate – form a protective barrier over the mouth, protecting it and providing pain relief while also promoting healing. Thanks to their innovative formula, Aftacure Gel and Aftacure Spray are indicated in the treatment of canker sores, irritation and lesions in the mouth due to oral surgery, traumatic ulcers caused by orthodontic devices or dentures. They act through film-forming properties, adhere to the mucosa and produce a barrier that helps to relieve pain and promote healing.

About  BMG Pharma S.r.l.

BMG Pharma S.r.l. is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health.  BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s key features are:
-Full involvement in business and partnering

-Presence in  different therapeutic areas

-Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to  allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical  data.

-IP protection for most of the products and technologies.

About Pierre Fabre and Pierre Fabre Oral Care
Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2015, it generated 2,208 million euros in net sales, of which 58% came from its international business and 57% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and employs around 13,000 people worldwide.
Pierre Fabre’s portfolio represent a continuum ranging from prescription drugs and consumer health care products to dermo-cosmetics. In 2015, the company dedicated almost 200 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.
Within Pierre Fabre Consumer Health Care division, Pierre Fabre Oral Care is the brand specialized in oral health care. It offers a comprehensive, balanced range of products to meet the needs of every individual, at every stage of their lives. Their purpose ranges from prevention to treatment and care, through daily hygiene. Present on every continent, Pierre Fabre Oral Care pursues global development while maintaining a strong regional base. Pierre Fabre Oral Care has successfully adapted its awareness-raising initiatives to the countries where it operate. Research & Development and production take place primarily in France, which guarantees traceability and high-quality products.
Pierre Fabre is mostly owned (86%) by the Pierre Fabre Foundation, a registered public-interest foundation, and secondarily by its own employees.

For press releases and other company information, visit :
and contact :  Mrs. Loredanan Galli

BMG Pharma s.r.l

Via Confalonieri 29

20124 Milano, Italy


Telephone number: +39 02 91321756